1416548-71-4

Basic information

• Product Name: 2-(4-(4-chlorobenzoyl)phenoxy)-N-(2-(4-hydroxyphenyl)-2-oxoethyl)-2-methylpropanamide
• Synonyms: 2-(4-(4-chlorobenzoyl)phenoxy)-N-(2-(4-hydroxyphenyl)-2-oxoethyl)-2-methylpropanamide
• CAS NO: 1416548-71-4
• Molecular Weight: 451.906
• Mol File: 1416548-71-4.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2-(4-(4-chlorobenzoyl)phenoxy)-N-(2-(4-hydroxyphenyl)-2-oxoethyl)-2-methylpropanamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-(4-chlorobenzoyl)phenoxy)-N-(2-(4-hydroxyphenyl)-2-oxoethyl)-2-methylpropanamide(1416548-71-4)
• EPA Substance Registry System: 2-(4-(4-chlorobenzoyl)phenoxy)-N-(2-(4-hydroxyphenyl)-2-oxoethyl)-2-methylpropanamide(1416548-71-4)

Safety Data

• Hazardous Substances Data: 1416548-71-4(Hazardous Substances Data)

Upstream product

• 42017-89-0 fenofibric acid 
• 77369-38-1 2-amino-1-(4-hydroxyphenyl)ethyl ketone 
• 17194-82-0 2-(4-hydroxyphenyl)acetamide 
• 2491-38-5 2-bromo-1-(4'-hydroxyphenyl)-1-ethanone 
• 19745-72-3 ω-amino-4-hydroxyacetophenone hydrochloride 

Relevant articles and documents

Discovery and synthesis of a novel series of liver X receptor antagonists

Fourteen novel compounds were prepared and their antagonistic activities against liver X receptors (LXR) α/β were tested in vitro. Compound 26 had an IC50 value of 6.4 μM against LXRα and an IC50 value of 5.6 μM against LXRβ. Docking studies and the results of structure-activity relationships support the further development of this chemical series as LXRα/β antagonists.

AMIDE COMPOUND, PREPARATION METHOD AND USES THEREOF

Disclosed are amide compounds, preparation method and uses thereof, specifically, the compounds represented by formula I or pharmaceutically acceptable salts, wherein R1, R2, R3, R4, R5, Q, X and n are defined as in the description. Also disclosed are a method for preparing the compounds of formula I, a composition containing the compounds, and the uses of the same in the preparation of medicaments for regulating blood lipid and/or preventing gallstone. The compounds of formula I disclosed in the present invention have stability in vitro, good solubility in the pharmaceutical organic solvents and favorable bioavailability in animals.